| 词条 | Lexatumumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 458270193 | image = | type = mab | mab_type = mab | source = u | target = TRAIL-R2 | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 845816-02-6 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 967Q0SJD77 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D06611 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | C=6346 | H=9832 | N=1720 | O=2002 | S=42 | molecular_weight = 143.6 kg/mol }}Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer.[1] HGS-ETR2 antibodies were generated by HGS through a collaboration with Cambridge Antibody Technology.[2] Development was discontinued in 2015.[3] References1. ^Statement on a Nonproprietary Name adopted by the USAN Council - Lexatumumab, American Medical Association. {{Monoclonals for tumors}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^{{cite web |url=http://www.hgsi.com/trail-receptor-antibodies-5.html |title=Archived copy |accessdate=2010-05-12 |deadurl=yes |archiveurl=https://archive.is/20080516025527/http://www.hgsi.com/trail-receptor-antibodies-5.html |archivedate=2008-05-16 |df= }} 3. ^{{cite web|title=Lexatumumab - AdisInsight|url=https://adisinsight.springer.com/drugs/800017268|website=adisinsight.springer.com|language=en}} 2 : Monoclonal antibodies for tumors|Experimental cancer drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。